BofA Maintains Neutral on Recursion Pharmaceuticals (RXRX) Feb 25, 2026

Bank of America Securities on Feb 25, 2026 maintained a Neutral rating on Recursion Pharmaceuticals, Inc. (RXRX) and lowered its price target to $6. The update is the primary RXRX analyst rating action this week and signals tempered expectations on near-term commercial timing. Investors should note the PT cut despite the unchanged Neutral stance. This RXRX analyst rating matters for shareholders who track sell-side guidance and for traders watching reaction to guidance and earnings updates.